Description
ADCC-Enhanced anti-CFR-1 (PAM-1) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CFR-1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
GLG1
Full Name
gastrokine 1
Alternative Names
GLG1; golgi glycoprotein 1; CFR-1; ESL-1; MG160; MG-160; Golgi apparatus protein 1; E-selectin ligand 1; golgi sialoglycoprotein MG-160; cysteine-rich fibroblast growth factor receptor
Gene ID
2734
UniProt ID
Q9UK05
Cellular Localization
Golgi apparatus, Cytoskeleton
Involvement in Disease
Diseases associated with GLG1 include Ecthyma and Trichinosis.
Related Pathways
Its related pathways are Cell surface interactions at the vascular wall and Apoptotic Pathways in Synovial Fibroblasts.
Function
Binds fibroblast growth factor and E-selectin (cell-adhesion lectin on endothelial cells mediating the binding of neutrophils).
Post-translational modifications
1.Fucosylation is essential for binding to E-selectin 2.Modification sites at PhosphoSitePlus 3.N-glycosylated. Contains sialic acid residues 4.Glycosylation at Asn165, Asn210, Asn581, Asn677, Thr739, and Asn786
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
PAM-1
Description
The human antibody PAT-PA1 has already been shown to effectively kill a number of different types of cancer, including significantly reducing gastric and pancreatic tumours in animal models of human cancer, with no adverse side effects.
Antibody Indication
Cancer
